July 26th 2024
“This highlights a need for physicians to better integrate patient preferences into their treatment recommendations," says Jonathan Bergman, MD, MPH.
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Differences in health care access may drive prostate cancer disparities
October 31st 2023“It was interesting to find that when Black and White men were provided equal access to the same therapies, given at the same dosage and monitored in the same setting, disparities in outcomes were eliminated," says Jun Gong, MD.
Enzalutamide data published in NEJM as FDA weighs nonmetastatic HSPC approval
October 20th 2023The phase 3 EMBARK trial showed that enzalutamide plus leuprolide reduced the risk of metastasis or death by nearly 60% vs leuprolide alone in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Choosing Partners in Cancer Care: A Strategic Approach
October 20th 2023Delve into the strategic process of selecting ideal partners in cancer care as key opinion leaders share insights on building trust, effective communication, and optimizing patient outcomes through collaborative decision making.
Expert on prostate cancer drug cost savings with the Inflation Reduction Act
October 17th 2023"Hopefully this law will allow more patients with advanced prostate cancer to gain access to these medications, and to take it without substantially changing the quality of their life when it comes to financial consequences," says Benjamin Pockros, MD.
Dr. Samuel Washington III on setting patient expectations after prostate cancer treatment
October 16th 2023"Hopefully this gives patients and providers information that they can use to inform and set reasonable expectations of what patient's lives will look like after treatment," says Samuel L. Washington III, MD, MAS.